Form 4 for EW Edwards Lifesciences
Accepted 2025-05-09 00:00:00 ET · period of report 2025-05-07 · accession 0001225208-25-004945 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-09 | 2025-05-07 | EW | Markowitz Wayne | SVP, GM, Surgical | F - Tax | $74.92 | -300 | 8,999 | -3% | -$22.5K |
| D | 2025-05-09 | 2025-05-07 | EW | Markowitz Wayne | SVP, GM, Surgical | S - Sale | $75.08 | -268 | 9,299 | -3% | -$20.1K |
| D | 2025-05-09 | 2025-05-08 | EW | Markowitz Wayne | SVP, GM, Surgical | A - Grant | $0.00 | +3,350 | 12.3K | +37% | $0 |
| DM | 2025-05-09 | 2025-05-08 | EW | Markowitz Wayne | SVP, GM, Surgical | A - Grant | $0.00 | +20.4K | 3,350 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-07 | F | D | 300 | $74.92 | 8,999.19 | D | — | — | |
| 2 | Common | Common Stock | 2025-05-07 | S | D | 268 | $75.08 | 9,299.19 | D | — | — | |
| 3 | Common | Common Stock | 2025-05-08 | A | A | 3,350 | $0.00 | 12,349.19 | D | — | — | (F1) These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
| 4 | Derivative | Employee Stock Option (Right to Acquire) | 2025-05-08 | A | A | 17,100 | $0.00 | 17,100 | D | $74.63 · 2026-05-08 to 2032-05-07 | 17,100 Common Stock | (F2) These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
| 5 | Derivative | Performance Rights | 2025-05-08 | A | A | 3,350 | $0.00 | 3,350 | D | — · 2028-05-08 to — | 3,350 Common Stock | (F3) Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. |